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CHEMOKINES
Bone marrow mesenchymal stem cells express a restricted set of functionally
active chemokine receptors capable of promoting migration to pancreatic islets
Valeria Sordi, Maria Luisa Malosio, Federica Marchesi, Alessia Mercalli, Raffaella Melzi, Tiziana Giordano, Nathalie Belmonte,
Giuliana Ferrari, Biagio Eugenio Leone, Federico Bertuzzi, Gianpaolo Zerbini, Paola Allavena, Ezio Bonifacio, and Lorenzo Piemonti
Bone marrow–derived mesenchymal stem
cells (BM-MSCs) are stromal cells with
the ability to proliferate and differentiate
into many tissues. Although they repre-
sent powerful tools for several therapeu-
tic settings, mechanisms regulating their
migration to peripheral tissues are still
unknown. Here, we report chemokine re-
ceptor expression on human BM-MSCs
and their role in mediating migration to
tissues. A minority of BM-MSCs (2% to
25%) expressed a restricted set of chemo-
kine receptors (CXC receptor 4 [CXCR4],
CX3C receptor 1 [CX3CR1], CXCR6, CC
chemokine receptor 1 [CCR1], CCR7) and,
accordingly, showed appreciable chemo-
tactic migration in response to the chemo-
kines CXC ligand 12 (CXCL12), CX3CL1,
CXCL16, CC chemokine ligand 3 (CCL3),
and CCL19. Using human pancreatic is-
lets as an in vitro model of peripheral
tissue, we showed that islet supernatants
released factors able to attract BM-MSCs
in vitro, and this attraction was princi-
pally mediated by CX3CL1 and CXCL12.
Moreover, cells with features of BM-MSCs
were detected within the pancreatic islets
of mice injected with green fluorescent
protein (GFP)–positive BM. A population
of bona fide MSCs that also expressed
CXCR4, CXCR6, CCR1, and CCR7 could
be isolated from normal adult human pan-
creas. This study defines the chemokine
receptor repertoire of human BM-MSCs
that determines their migratory activity.
Modulation of homing capacity may be
instrumental for harnessing the therapeu-
tic potential of BM-MSCs. (Blood. 2005;
106:419-427)
© 2005 by The American Society of Hematology
Introduction
Bone marrow (BM) is a complex tissue containing hematopoietic
progenitor cells and a connective-tissue network of stromal cells.
Marrow stroma includes a subpopulation of undifferentiated cells
that are capable of becoming one of a number of phenotypes,
including bone and cartilage, tendon, muscle, fat, and marrow
stromal connective tissue that supports hematopoietic cell differen-
tiation.1,2 These cells are referred to as mesenchymal stem cells
(MSCs), since they are known to have capacity of proliferation and
differentiation into the mesenchymal lineage. Due to their potential
for differentiation into different tissues, MSCs have emerged as a
promising tool for clinical applications such as tissue engineering
and cell and gene therapy.3-5
Several reports underline the ability of MSCs to migrate.6-13
MSCs are thought to migrate in the bloodstream to seed new sites
of hematopoiesis and to various tissues during embryonic and fetal
development.14,15 MSCs are present in large numbers in human
blood from at least 7 weeks’ gestation and they persist until
approximately 12 weeks’ gestation.14 Although circulating MSCs
decrease after 12 weeks, there is evidence that a very low-
frequency population of circulating multipotent nonhematopoietic
cells resembling the classical MSCs persist through to adult
life.16-18 MSCs migrate efficiently to hematopoietic tissues (BM
and spleen) after transplantation in some experimental animal
models,19,20 whereas reports of BM homing in humans are inconsis-
tent.21-26 Of particular interest for tissue remodeling, intravenous
delivery of MSCs results in their specific migration to a site of
injury.6-8,10,27 This ability of implanted MSCs to seek out the site of
tissue damage has been demonstrated in bone or cartilage frac-
ture,28 myocardial infarction,8,29 and ischemic cerebral injury.6,10,11
Because MSCs have been shown to give rise to many tissues (such
as bone, cartilage, fat, endothelia, muscle, brain, and pancreatic
islet cells30,31), migrating MSCs may represent a source of pluripo-
tent cells that are constantly available for the repair of damaged
organs. The mechanisms that guide homing of implanted cells are
unclear. In this study, we examined the role of chemokines and
their receptors in the migration of human MSCs. Moreover the
interaction between human pancreatic islets and MSCs was investi-
gated as a model of tissue cross talk.
Material and methods
Human bone marrow mesenchymal stem cell culture
Human bone marrow mesenchymal stem cells (BM-MSCs) were obtained
from Cambrex (Baltimore, MD). There were 3 different batches used for the
study. Before use, the cells were analyzed for morphology, marker
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expression, and osteogenic differentiation. All batches used had a fibroblast-
like morphology in culture, were homogeneously CD73, CD105, HLA
I, V3, V5, CD34, CD45, CD117, CD31, HLAII, CD18,
CD80, CD86, and CD40, and were able to differentiate to osteoblasts.
Cells were grown in -Minimum Essential Medium (-MEM; Biochrom,
Berlin, Germany) supplemented with 10% fetal bovine serum (FBS;
Hyclone, Logan, UT). Cells were passaged twice prior to use by trypsiniz-
ing and subculturing at a 1:6 dilution. BM-MSCs were cultured in 6-well
multiwell tissue culture plate (Falcon; Becton Dickinson, Franklin Lakes,
NJ), replacing medium twice a week.
Isolation of tissue MSCs from human pancreas
Primary human pancreatic tissues were obtained from the digest remaining
after the isolation of islet cells from human pancreas, as previously
described.32 The dense fraction recovered in the pellet and normally
discarded was processed for MSC isolation. Following 2 washes in
phosphate-buffered saline (PBS), the equivalent of 1 mL packed pellet was
resuspended in -MEM and 10% FBS, plated in one T75 tissue culture–
treated flask (Costar, Cambridge, MA), and grown at 37°C in a humidified
incubator at 5% CO2. After 24 hours, the nonadherent material was
removed and fresh medium added to the cells. Medium was changed every
3 days. Cells were harvested by trypsinization and either passaged for
expansion purposes or subjected to analysis. MSCs derived from 3 pancreas
preparations were used.
Osteogenic differentiation of MSCs
For the differentiation assay, cells were seeded following trypsinization into
6-well tissue culture–treated plates and grown to confluency. Differentia-
tion was started by adding complete medium containing 1 nM dexametha-
sone, 20 mM -glycerolphosphate, and 50M L-ascorbic acid 2-phosphate.
After 21 days, cells were fixed in 4% paraformaldehyde and stained with a
solution of 1% alizarin red. Cells were photographed under an inverted
microscope (Leica DMIRB equipped with a 5 /0.15 numerical aperture
objective and a Leica DC300Fx digital camera and Leica IM50 software;
Leica Camera AG, Solms, Germany).
Flow cytometry analysis of surface antigens
Human BM-MSCs at passage 2 and human pancreatic MSCs at passage 4
were treated with 0.25% trypsin–EDTA (ethylenediaminetetraacetic acid),
harvested, and washed twice with -MEM. Before staining, cells were
allowed to recover expression of surface markers for 2 hours in suspension.
Cell staining was performed using mouse monoclonal antibodies (mAbs)
followed by fluorescein isothiocyanate (FITC)–conjugated affinity-
purified, isotype-specific goat anti–mouse immunoglobulin G (IgG) F
(ab)2 antibodies (Jackson ImmunoResearch Laboratories, West Grove,
PA). The following mAbs were used in this study: L243 (IgG2a anti–major
histocompatibility complex [MHC] class II) from American Type Culture
Collection (ATCC, Rockville, MD); BB1 (IgM, anti-CD80), BU63 (IgG1,
anti-CD86), and EA-5 (IgG1 anti-CD40) from Ancell (Bayport, MN); AD2
(IgG1, anti CD73) from BD PharMingen (San Diego, CA); 44716 (IgG2b
anti–CXC receptor 4 [CXCR4]), 150503 (IgG2a anti–CC chemokine
receptor 7 [CCR7]), 53504.111 (IgG2b, anti-CCR1), 56811.111 (IgG2b,
anti-CXCR6), and 166707 (IgG1 anti-CD105) from R&D System (Minne-
apolis, MN); 2A9-1 (rat IgG2b anti–CX3C receptor 1 [CX3CR1]) from
MBL (Woburn, MA); 57A5 (IgG1 anti-CD117) from Kamiya Biomedical
Company (Seattle, WA); 581 (IgG1 anti-CD34), H130 (IgG1 anti-CD45),
and MBC78.2 (IgG1 anti-CD31) from Caltag Laboratories (Burlingame,
CA); and LM609 (IgG1 anti-v3) and PF16 (IgG1 anti-v5) from
Chemicon (Temecula, CA). Cells were analyzed with a FACScalibur flow
cytometer. Results are expressed as the mean percentage of positive cells
and standard deviation from multiple experiments.
Chemotaxis assay
Cell migration was evaluated using a 48-well modified Boyden chamber as
previously described, with minor modifications.33 The polycarbonate filter
(12-m pore size, CN110416; Neuroprobe, Bethesda, MD) was precoated
with fibronectin (5 g/mL; Sigma Chemical, St Louis, MO); cells were
resuspended at 5  105/mL in the appropriate medium supplemented with
1% FBS and seeded in the upper chamber. Recombinant CXC ligand 12
(CXCL12), CX3C ligand 1 (CX3CL1), CC chemokine ligand 3 (CCL3),
CCL19 (Peprotech, Rocky Hill, NJ), and CXCL16 (R&D System) were
used as chemoattractants in the lower compartment. The chambers were
incubated overnight at 37°C. Results are expressed as the mean number of
net migrated cells over control cells (basal migration without chemotactic
stimulus), counted in 10 microscope fields at high-power magnification
( 1000). Each experiment was performed in triplicate. Where indicated,
cells were incubated with blocking mAbs against CXCR4 (12G5, 10
g/mL; R&D System) and/or CX3CL1 (81 506, 10 g/mL; R&D System).
Chemokine and cytokine assays
For MSCs, supernatant was collected after 48 hours of culture. For human
pancreatic islets, supernatant was collected after 48 hours of culture in the
presence or absence of interleukin-1 (IL-1, 10 ng/mL; R&D System).
Human islets were obtained from cadaveric donors and were isolated using
a modification of the Ricordi method as previously described.32 Islets used
for chemokine and migration experiments were handpicked. Chemokines
and cytokines were quantified by SearchLight Human Proteoma Array
(Pierce Endogen, Woburn, MA) according to the manufacturer’s instruc-
tions. CX3CL1 and CCL12 were also measured by enzyme-linked immu-
nosorbent assay (ELISA) with commercial kits (R&D System).
RT-PCR
Total RNA was extracted with Trizol-LS reagent (Invitrogen, Carlsbad,
CA). For reverse-transcriptase–polymerase chain reaction (RT-PCR), cDNA
was synthesized in a 20-L reaction volume containing 4 g total RNA and
SuperScript III RT (Invitrogen), according to the manufacturer’s instruc-
tions. The endogenous gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was also quantified to normalize differences in the added RNA
and efficiency of reverse transcription. The thermal profile for PCR with
FastStartTaq (Roche Diagnostics, Penzberg, Germany) was 94°C for 5
minutes, followed by 35 cycles of 30 seconds at 94°C, with 1-minute
annealing intervals (57°C for chemokine receptors) followed by 1-minute
extension at 72°C. The PCR products were size-fractioned by electrophore-
sis on 2% agarose gels. The specific primers used are shown in Table 1.
Animal model for BM cell migration to pancreatic islets
BM transplantation experiments were performed using a green fluorescent
protein (GFP) transgenic strain as a donor and a coisogenic strain,
expressing the allelic form of CD45 antigen (CD45.1) as recipient. Murine BM
cells were harvested from 7-week-old male C57BL/6-TgN(ACTbEGFP)1Osb
mice (Jackson Laboratories, Bar Harbor, ME) by flushing femurs and tibiae.
Per mouse, 3  106 donor BM cells were injected into the tail vein of
recipient 7-week-old C57BL/6-CD45.1 mice (B/6.SJL-CD45a-Pep3b; Jack-
son Laboratories), lethally irradiated with a dose of 975 cGy. Mice were
killed 2 to 13 weeks after BM transplantation, hematopoietic tissues (BM,
spleen, and thymus) were collected for flow cytometry analysis, and
pancreata were isolated for immunohistochemistry and in vitro cultures. All
the described experiments were approved by the Institute’s Animal Care
and Use Committee.
Immunofluorescence and immunohistochemistry
For tissue section analysis, animals were anesthetized and perfused intracardially
with 4% paraformaldehyde/PBS. Perfused pancreata were dissected and further
fixed in 4% paraformaldehyde at 4°C for one hour. Fixed organs were washed
with PBS, cryoprotected by incubation in increasing concentration of cold
sucrose (10%, 20%, and 30%; total 12-24 hours), and quick-frozen in cryo-
embedding compound (Microm International, Walldorf, Germany). For intrinsic
GFP analysis, 10-m frozen sections were cut from several distinct lobes and
mounted using VECTASHIELD with 4, 6-diamidino-2-phenylindole (DAPI;
Vector Laboratories, Burlingame, CA). Double immunohistochemical staining
on 10-m frozen pancreatic sections was performed with a polyclonal guinea pig
anti-insulin (DAKO, Carpinteria, CA) and a polyclonal rabbit antiglucagon
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(DAKO) antisera using a standard protocol.AffiniPure anti–guinea pig tetrameth-
ylrhodamine-5(and 6)-isothiocyanate (TRITC) and anti–rabbit cyanin 5 (Cy5)
secondary antibodies (Jackson ImmunoResearch Laboratories) were used for
detection. Tissue sections were counterstained with DAPI prior to mounting.
For ex vivo analysis of islets, animals were killed and pancreata were
removed immediately. Islets were isolated as previously described34 and
kept in culture in RPMI containing 10% FBS in 6-well plates for the
appropriate times or plated on poly-L-lys–coated coverslips for immunoflu-
orescence staining. A Leica TCS SP2 AOBS confocal scanning microscope
equipped with a 63 oil immersion objective (numerical aperture 1.4) was
used to image the results. Adobe Photoshop v.5.02 (Adobe, San Jose, CA)
was used to visualize the images and to compose the final pictures.
Results
Expression of chemokine receptors and chemokines
in BM-MSCs
CC, CXC, CX3C, and C chemokine receptor expression on
BM-MSCs was examined in order to determine potential migratory
stimuli. BM-MSCs expressed the transcripts for CCR1, CCR7,
CXCR4, CXCR6, and CX3CR1 (Figure 1A). Transcripts for other
chemokine receptors were not detected. Protein expression was
determined by fluorescence-activated cell sorter (FACS) analysis
(Figure 1B). The expression of chemokine receptors appeared
heterogeneous. A small percentage of cells was positive for CCR1
and CCR7 (1.8  2.7% and 2  2.4%, respectively; n 	 5), and a
higher percentage of cells, but not all cells, was positive for
CXCR6, CX3CR1, and CXCR4 (respectively 22  5%, 20  9%,
and 26  2.4%; n 	 5).
BM-MSCs secrete several hematopoietic cytokines supporting
the growth of hematopoietic progenitors.1,2 We therefore tested if
they can produce chemokines that are known to bind to the
BM-MSC chemokine receptors and therefore able to act in an
autocrine manner. BM-MSCs were cultured for 7 days. High
amounts of CXCL8, CXCL12, CCL2, CCL5, and vascular endothe-
lial growth factor (VEGF) and a low amount of CCL3 and
angiopoietin 2 were detected in the culture supernatant (Figure
2A). BM-MSCs, therefore, not only express chemokine receptors
but also are able to secrete some chemokines that can act in an
autocrine loop (ie, CXCL12-CXCR4).
BM-MSCs migrate in response to specific chemokine gradients
The ability of BM-MSCs to migrate in response to chemotactic
signals was investigated using a micromultiwell chemotaxis cham-
ber assay. The following ligand-receptor combinations were inves-
tigated: CX3CL1 (fractalkine) for CX3CR1; CCL3 (macrophage
inflammatory protein 1 [MIP1]) for CCR1; CCL19 (MIP3)
and CCL21 (secondary lymphoid-tissue chemokine [SLC]) for
CCR7; CXCL12 (stromal-derived factor 1 [SDF1]) for CXCR4;
and CXCL16 for CXCR6. BM-MSCs migrated in a dose-
dependent manner to different concentrations of CXCL12, CX3CL1,
CXCL16, CCL3, CCL19, and CCL21 (Figure 2B). Pretreatment of
BM-MSCs with a blocking anti-CXCR4 mAb (10 g/mL) or with
anti-CX3CL1 mAb (10 g/mL) abrogated cell migration in
response to CXCL12 and CX3CL1, respectively, confirming the
specificity of the migration (data not shown).
Table 1. Primers used for chemokine receptor detection
Gene Oligonucleotide forward Oligonucleotide reverse
Insulin 5CTTTGTGAACCAACACCTGTG 3 5GTTGCAGTAGTTCTCCAGTG 3
Cxcr1 5GGCTGCTGGGGACTGTCTATGAAT 3 5GCCCGGCCGATGTTGTTG 3
Cxcr2 5CCGCCCCATGTGAACCAGAA 3 5AGGGCCAGGAGCAAGGACAGAC 3
Cxcr3 5CAACGCCACCCACTGCCAATACAA 3 5CAGGCGCAAGAGCAGCATCCACA 3
Cxcr4 5AGCTGTTGGCTGAAAAGGTGGTCTATG 3 5GCGCTTCTGGTGGCCCTTGGAGTGTG 3
Cxcr5 5AACTACCCGCTAACGCTGGAAATGGAC 3 5CACGGCAAAGGGCAAGATGAAGACC 3
Cxcr6 5ATGGCAATGTCTTTAATCTCGACAA 3 5TGAAAGCTGGTCATGGCATAGTATT 3
Ccr1 5CAACTCCGTGCCAGAAGGTGAA 3 5GCCAGGGCCCAAATGATGAT 3
Ccr2 5CCAACGAGAGCGGTGAAGAAGTC 3 5TCCGCCAAAATAACCGATGTGAT 3
Ccr3 5GAGCCCGGACTGTCACTTTTG 3 5CAGATGCTTGCTCCGCTCACAG 3
Ccr4 5AAGAAGAACAAGGCGGTGAAGATG 3 5AGGCCCCTGCAGGTTTTGAAG 3
Ccr5 5CTGGCCATCTCTGACCTGTTTTTC 3 5CAGCCCTGTGCCTCTTCTTCTCAT 3
Ccr6 5CCTGGGGAATATTCTGGTGGTGA 3 5CATCGCTGCCTTGGGTGTTGTAT 3
Ccr7 5GTGCCCGCGTCCTTCTCATCAG 3 5GGCCAGGACCACCCCATTGTAG 3
Ccr8 5GGCCCTGTCTGACCTGCTTTTT 3 5ATGGCCTTGGTCTTGTTGTGGTT 3
Ccr9 5CACTGTCCTGACCGTCTTTGTCT 3 5CTTCAAGCTTCCCTCTCTCCTTG 3
Ccr10 5TGCTGGATACTGCCGATCTACTG 3 5TCTAGATTCGCAGCCCTAGTTGTC 3
Xcr1 5TGACCATCCACCGCTACC 3 5ATCTGGGTCCGAAACAGC 3
Cx3cr1 5TCCTTCTGGTGGTCATCG 3 5TGTGCATTGGGTCCATCA 3
GADPDH 5GCCAAGGTCATCCATGACAACTTTGG 3 5GCCTGCTTCACCACCTTCTTGATGTC 3
Figure 1. BM-MSCs express chemokine receptors. (A) RT-PCR expression of
chemokine receptor mRNA in BM-MSCs. Human activated peripheral blood mono-
nuclear cells (PBMCs) or splenocytes were used as positive controls (Ctrl). (B)
Surface expression of CCR1, CCR7, CXCR6, CX3CR1, and CXCR4 on BM-MSCs
detected by flow cytometry. A representative experiment of 5 is shown. The mean 
SD percentage of positive cells is indicated (n 	 5). Open curves refer to control
antibody signal; shaded curves refer to specific antibody signal.
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Pancreatic islets secrete chemokines that attract BM-MSCs
Several recent in vivo studies35-37 demonstrated that BM can
contribute to pancreatic  cell regeneration,36 and mesenchymal
stem cells were proposed as the BM cell type responsible for
pancreatic endocrine differentiation.38,39 We therefore studied
pancreatic islets for their ability to secrete chemokines and
attract BM-MSCs.
Chemokine concentrations were measured in the supernatants
of 3 primary cultures of human pancreatic islets. There were 100
human islets purified by handpicking and cultured for 48 hours in
the presence or absence of IL-1 (10 ng/mL). Chemokine release
was evaluated by search light proteoma array and ELISA. High
amounts of CCL2, CXCL1, CXCL8, and CXCL12, and less of
CX3CL1, CCL3, and CCL20 were detected in the culture medium
(Figure 3A). Since BM-MSCs express the receptors for CX3CL1
and CXCL12, these 2 factors were studied further. Human islets
released CXCL12 and CX3CL1 in a time-dependent manner
(Figure 3B). Whole pancreas sections from surgical specimens
(tumor, n 	 3; pancreas from explanted organs, n 	 2) were
examined for CXCL12 and CX3CL1 protein expression by immu-
nohistochemistry. Both CXCL12 and CX3CL1 were visualized
within the cytoplasm of islet cells. A less intensive staining was
seen in ductal cells (in particular, small ducts), whereas the
exocrine tissue appeared negative.
To investigate the ability of human pancreatic islets to attract
BM-MSCs, we tested islet supernatants as chemoattractants for
BM-MSCs in vitro. Islet supernatants were able to attract human
BM-MSCs in a classical chemotaxis assay (Figure 3C). Superna-
tants from 4 islet preparations induced migration of 39  6,
38  4, 35  4, and 38  5 BM-MSCs/10 HPFs. The chemotactic
activity decreased after supernatant dilution showing a dose
dependency. Addition of 10 ng/mL IL- to islet cultures did not
increase migration of BM-MSCs.
To investigate whether CXCL12 and CX3CL1 were responsible
for the chemotactic activity of islet supernatants, abrogation of
BM-MSC migration was sought using specific blocking antibodies
(Figure 3D). Migration of BM-MSCs was inhibited by pretreat-
ment with blocking anti-CXCR4 mAb or anti-CX3CL1 mAb, and
this inhibition was even more pronounced when both antibodies
were added. These data indicate that CXCL12 and CX3CL1 are the
major chemokines for BM-MSC migration found in the superna-
tant of human pancreatic islets.
BM-derived cells migrate to islets in an in vivo
experimental model
To investigate the ability of pancreatic islets to attract BM-MSCs in
vivo, we analyzed the islet recruitment of BM cells in a model of
BM transplantation (BMT). Total BM cells from donor GFP
transgenic mice (C57BL/6-TgN(ACTbEGFP)1Osb), which ex-
press GFP in all the nucleated cells, were transplanted into lethally
irradiated coisogenic recipient C57BL/6-CD45.1. Animals were
killed 2 to 13 weeks after transplantation, and the hematopoietic
cell populations were analyzed by flow cytometry for donor
chimerism. All mice that underwent transplantation showed a high
level of BM chimerism, scored as CD45.2/CD45.2  CD45.1
ratio (mean 92  6.5%, 89  10%, and 93  4%, respectively, for
mice killed at 11, 12, and 13 weeks after BMT) (data not shown).
Analysis of pancreatic sections obtained 2 weeks after BMT
showed that GFP BM graft–derived cells localized around and
inside the islets (Figure 4A). In separate experiments, islets were
isolated 11 weeks (n 	 5), 12 weeks (n 	 5), or 13 weeks (n 	 5)
after BMT and GFP cells were counted. The isolated pancreatic
islets of all animals contained donor-derived GFP cells
(Figure 4B-C).
Isolated islets were cultured in standard conditions for 4 weeks.
Starting from day 2, the number of GFP cells inside the islets
increased, and a heterogeneous population of GFP cells ranging
from narrow spindle shaped to large polygonal cells colonized the
culture dishes and proliferated (Figure 5A). Marked expansion of
GFP cells was observed during the first week for all islet cultures.
Further expansion after 1 week was observed for islets isolated 13
weeks after BMT. Most GFP BM cells obtained from islets
showed a fibroblast-like morphology and did not costain with an
antibody against CD45 but were positive for stem cell antigen 1
(Sca-1) (after 1 week of culture 35  5% of the GFP cells were
Sca-1, 13  4% of the GFP were CD45), indicating that
CD45/Sca-1 BM cells were recruited to islets in vivo, and that
these cells were able to survive and proliferate after islet isolation
(Figures 5B,6A). To unequivocally demonstrate that the GFP cells
obtained from islet are MSCs, we tested their ability to differentiate
along the osteoblastic lineage (Figure 6B). After 3 weeks of culture
under standard conditions for osteogenesis, 65  20% (mean of 10
fields) of the GFP cells stained positive for the osteoblast marker
alizarin red. Most, but not all, of the alizarin red–positive cells
appeared GFP (75  15%), showing that donor BM-derived
MSCs were the major but not the unique source of islet-derived
cells able to differentiate along an osteoblastic lineage.
Tissue MSCs resembling BM-MSCs can be isolated from
human pancreas
Using the physical property of plastic adherence with a similar
methodology to that originally used by Friedenstein40 and Goshima
et al,41 we were able to isolate a population of bona fide MSCs from
human adult pancreas. Briefly, the digest remaining after the
isolation of islet cells from human pancreas was kept in culture.
After 1 to 3 days, the nonadherent tissue was removed with a
medium change, and the adherent, or residual, cells were expanded
Figure 2. BM-MSCs produce chemokines and chemokines stimulate BM-MSC
chemotaxis. (A) Chemokine/growth factor concentrations in supernatants from
2  105 BM-MSCs cultured in 3 mL medium for 7 days. Results are expressed as
mean  SD (n 	 3). # indicates upper range of measurement (4 ng/mL for CXCL8,
CXCL12, CCL2; 1 ng/mL for CCL5). (B) Migration of BM-MSCs to different
concentrations of CX3CL1, CXCL12, CXCL16, CCL3, CCL19, and CCL21 in a
chemotaxis assay. Shown are numbers of migrated cells counted in 10 high-power
fields (HPFs) after subtraction of the basal migration observed in the absence of
chemokine. Basal migration was 10  5 cells/10 HPFs (*P 
 .05 versus control).
Values are the mean  SE of 8 replicates. Results are from 1 experiment of 3
performed.
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for up to 4 weeks with additional media changes every 2 to 3 days.
After 3 weeks, most, if not all, adherent cells were in monolayer.
The population appeared quite homogenous with a fibroblast-like
morphology resembling BM-MSCs (Figure 7B). Phenotypically,
these cells expressed the markers of MSCs. They were CD73 (Src
homology 3 [SH3] or SH4), CD105 (SH2), V/3, V/5,
CD45, CD34, CD31, and CD117 (Figure 7A). Moreover they
maintained the ability to proliferate in culture even after 9 months
of culture. To identify these cells unequivocally as MSCs, we
induced their differentiation into bone in vitro. After culture under
Figure 3. Human islets produce chemokines and attract BM-MSCs by secreting CXCL12 and CX3CL1. (A) Chemokines/growth factors measured in the supernatant of
100 handpicked human pancreatic islets after 48 hours of culture in the presence or absence of IL-1 (10 ng/mL). Results are expressed as mean SD from 3 experiments. (B,
left) Release of CXCL12 and CX3CL1 from human pancreatic islet preparation cultured in the presence or absence of IL-1 (10 ng/mL) for up to 8 days. Results are the mean
SD from 6 islet preparations. (Right) Immunohistochemical detection of CXCL12 and CX3CL1 in human pancreas sections. Anti-CXCL12 and anti-CX3CL1 antibodies stained
the cytoplasm of islet cells and small duct cells. (C) Chemotaxis assay showing migration of BM-MSCs to supernatants of human islets cultured with (u) or without () IL-1 (10
ng/mL). The mean  SE of 8 replicates is shown for each of 4 islet supernatants (Sup. 1 to 4). The effect of supernatant dilution on the chemotactic activity is shown for
supernatant 4. Chemotaxis is measured as the number of migrated cells counted in 10 HPFs after subtraction of the basal migration observed in the absence of chemokine.
Basal migration was 10  5 cells/10 HPFs. The migration to recombinant CXCL12 and CX3CL1 is shown for comparison. (D) Inhibition studies of BM-MSC migration to islet
supernatant. Supernatants were preincubated with 10 g/mL anti-CX3CL1, BM-MSCs were preincubated with 10 g/mL anti-CXCR4, or both conditions were observed.
Chemotaxis is measured as the number of migrated cells counted in 10 HPFs after subtraction of the basal migration observed in the absence of chemokine. Basal migration
was 8  4 cells/10 HPFs. Values are the mean SE of 8 replicates. *P 
 .02 versus islet supernatant; **P 
 .001 versus islet supernatant.
Figure 4. Pancreatic islets are able to attract BM-derived
cells. (A) Confocal microscopy analysis of GFP BM-derived
cells in pancreas 2 weeks after BMT. GFP BM cells localized
around and at lower extent inside the islet. Immunostaining
for insulin (red) and glucagons (blue). DAPI: nuclear staining.
(Aii-iii) Close-up view of the region marked in panel Ai. White
arrows point to the GFP cells localized around the islet that
are confirmed by the nuclear staining. (B-C) Islet isolated from
mice that underwent transplantation with GFP BM after 11
(exp 1), 12 (exp 2), and 13 weeks (exp 3). (B) Low-power
magnification ( 5) of islet representative of the 3 experi-
ments; left panel: phase contrast image; right panel: fluores-
cence image. (C) GFP cells inside the islets were counted
directly in floating isolated islets. Data are expressed as
number of GFP cells/islet (mean  SE); 150 islets were
evaluated for each experiment.
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standard conditions for osteogenesis, they produced proteoglycan-
rich bone nodules that stained positive by alizarin red (Figure 7C).
In FACS analysis, the expression of chemokine receptors appeared
heterogeneous also in the tissue MSC populations but with some
differences compared with BM-MSCs (Figure 7D). The expression
of CXCR6 and CXCR4 was similar between pancreas-derived
MSCs and BM-MSCs, whereas the percentage of CCR1 and
CCR7 was significantly higher in tissue MSCs than BM-MSCs,
and CX3CR1 was expressed in a very low fraction of pancreas-
derived MSCs (Figure 7E).
Discussion
The comprehension of the mechanism that regulates migration is
crucial to the success of any clinical strategy involving MSCs.
Here, we report the first detailed study to address the chemotactic
responsiveness of MSCs to chemokines. BM-MSCs released
chemokines and displayed a restricted response pattern to chemo-
kines. They migrated appreciably in response to CXCL12, CX3CL1,
CXCL16, CCL3, CCL19, and CCL21, and consistent with this they
expressed CXCR4, CX3CR1, CXCR6, CCR1, and CCR7. More-
over, using human pancreatic islets as in vitro and in vivo models,
we showed that tissue is able to attract BM-MSCs, and this
attraction in vitro is principally mediated by CX3CL1-CX3CR1
and CXCL12-CXCR4. Finally we were able to isolate a population
of bona fide MSCs from adult human pancreas that displayed a
distinct but overlapping pattern of chemokine receptor expression.
The current study examined isolated human BM-MSCs and
human pancreatic islets in vitro. The data give conclusive evidence
that BM-MSCs can migrate to specific chemokine gradients and to
tissue-released chemokines. Although human BM-MSCs are known
to migrate in vivo, it cannot be excluded that the in vitro findings
may be influenced by culture or BM-MSC manipulation.19,20
Among the culture conditions that could affect these findings, the
appreciable chemokine release by BM-MSCs is likely to negatively
affect migration in vitro. Despite these limitations, the findings
indicate that there is more than one migratory stimulus for
BM-MSCs, that such stimuli are readily found in certain differenti-
ated extrahematopoietic tissues, and, therefore, that BM-MSCs can
be mobilized to tissue either naturally or induced to migrate to
tissue. Moreover, the observations in the mouse indicate that
BM-MSCs can be mobilized to inflamed nonhematopoietic tissues
also in vivo. Although the mouse studies demonstrated that the BM
cells migrating to pancreatic islets were CD45 and had typical
characteristics of MSCs, which that included the capacity to
differentiate along an osteoblastic lineage, they were not performed
using a lineage-specific model of BM transplant, and therefore
cannot exclude that these GFPCD45 cells did not derive from
bone marrow precursors other than bona fide BM-MSCs, including
CD45 stem cells.42 The presence of a small percentage of
GFPCD45 cells and of GFP cells unable to differentiate along
the osteoblastic lineage also suggests that a proportion of GFP
cells found in pancreatic islets was derived from non–mesenchy-
mal stem cell sources found in the bone marrow such as macro-
phages and endothelial cells. Moreover, the in vivo experiments did
Figure 5. BM-derived CD45 can be isolated and expanded from pancreatic
islets. (A) GFP cells inside and outside islets after islet isolation and 4 weeks of
culture. Low-power magnification of islets representative of the 3 experiments
photographed under an inverted microscope after 1 week of culture. (i) Phase
contrast. (ii) Fluorescence image. Islets were photographed under an inverted
microscope at different time points during culture. The number of GFP cells was
calculated with Scion Imaging Software (Scion, Frederick, MD) (iii-iv). For cells found
inside islets (iii), data at each time point are expressed as the mean  SE GFP
cell/islet determined for 100 islets. For cells found outside islets (iv), an area from the
islet center corresponding to twice the islet diameter was outlined and cells scored in
the area not occupied by the islet. The data at each time point are expressed as the
mean  SE GFP cell/100 m2 non–islet area determined for 50 islets. (B) Staining
for CD45 (red) and GFP (green) of cells found outside isolated islets after 24 hours or
48 hours of culture. (Left) Confocal microscopy showing GFP/CD45 and GFP/
CD45 cells at 24 hours. (Right) Results (mean SE) of cell counting are expressed
as number of cells/field. At least 20 fields for each time point were counted.
Figure 6. BM-derived CD45 can be isolated and expanded from pancreatic
islets. (A) Staining for Sca-1 and GFP of cells found outside isolated islets after 7
days of culture. Results (mean) of cell counting are expressed as percent of the GFP
cells. (B) Alizarin red staining for detecting osteogenic differentiation of BM-derived
GFP cells isolated and expanded from pancreatic islet. Isolated islets were cultured
in standard conditions for 1 week, and after 3 weeks of osteogenesis conditions were
stained by alizarin red. A representative field photographed under an inverted
microscope. (Top) Fluorescence image. (Bottom) Phase contrast. The arrows point to
the GFP cells localized around the islet that are confirmed to be osteoblasts by
alizarin red.
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not investigate the signals that determine migration to the
inflamed tissue.
Our findings confirm that CXCL12-CXCR4 are involved in
MSC migration and this is conserved also in tissue MSCs.
CXCL12 and its ligand CXCR4 play an important role in homing
as shown by studies on engraftment of hematopoietic stem/
progenitor cells43 and on colonization of bone and bone marrow by
metastatic breast and prostate cancer cells.44 CXCR4 was also
recently reported to promote MSC migration to bone marrow.45
Moreover, the study of the expression of CXCL12 and CXCR4
from gastrulation to organogenesis in the mouse embryo provides
evidence of the continuous involvement of the CXCL12-CXCR4
axis during embriogenesis.46 The CXCL12-deficient mouse and the
corresponding CXCR4 mutants are the only known chemokine/
chemokine receptor mutants that display embryonic lethality, and
genetically deficient embryos display severe defects in their
gastrointestinal vasculature, cerebellar neurons migration, cardiac
ventricular septal closure, B-cell development, and hematopoietic
BM colonization.47,48 The extensive consequences observed in
different organs in the CXCL12/CXCR4 knock-out (KO) mice
indicate that this axis is an essential component of differentiation of
numerous tissues. Our findings indicate that MSCs are also likely
to contribute to this differentiation.
The expression of CX3CR1 by BM-MSCs was an unexpected
novel finding. Together with CXCL12-CXCR4, CX3CL1-CX3CR1
represented the major migration axis for BM-MSCs to tissue
stimuli in vitro. CX3CL1 can exist either as a soluble protein or as a
membrane-bound molecule. Both forms of CX3CL1 can mediate
adhesion of cells expressing CX3CR1. This activity, together with
its expression on endothelial cells after exposure to inflammatory
mediators (tumor necrosis factor  [TNF-], IL-1, lipopolysaccha-
ride [LPS], and interferon  [INF]), suggests that CX3CL1 might
mediate adhesion of BM-MSCs to the endothelium during inflam-
mation after tissue injury. Our findings with respect to CX3CR1
and CXCR4 receptor expression are consistent with a report
showing that CXCL12-CXCR4 and CX3CL1-CX3CR1 interac-
tions mediate the trafficking of transplanted MSCs in a rat model of
left hypoglossal nerve injury.6 Both sets of findings are, however,
inconsistent with a previous study showing that CCL2 in cerebral
ischemic tissue promotes migration of infused MSCs to the site of
injury.11 We did not find expression of the receptor for CCL2,
CCR2, on human BM-MSCs, suggesting that CCL2-CCR2 interac-
tion on MSCs may be specific for the rat model.
Although both CXCL12-CXCR4 and CX3CL1-CX3CR1 con-
tributed to BM-MSC migration, it is unclear whether they operate
synergistically or if they act in response to distinct stimuli.
Redundancy for the CX3CL1-CX3CR1 migration axis is suggested
by CX3CL1 gene disruption in the mouse. These mice do not have
overt abnormalities in development, hematologic profile, lymphoid
tissue structure, and response to inflammatory stimuli,49 but a
specific study of MSCs in this model has not been performed. Our
findings that other less well-characterized chemokine receptor axes
such as CXCL16-CXCR6 could play a role in MSC migration also
support redundancy in the determinants of MSC migration. CXCR6
is a newly characterized chemokine receptor that until now was
described to be expressed selectively by subsets of memory/
effector T cells,50,51 natural killer (NK) cells,50 NKT cells,52 and
plasma cells.53 The CXCR6 ligand, CXCL16 was found to be a
Figure 7. Characterization of tissue pancreatic MSCs. (A) Surface marker profile of pancreatic MSCs after 3 weeks of culture (top row) and BM-MSCs (bottom row). Open
curves refer to control antibody signal; shaded curves refer to specific antibody signal. Results are from 1 experiment of 3 performed. (B) Morphology of BM-MSCs and tissue
pancreatic MSCs. Both MSCs appeared adherent in monolayer with a fibroblast-like morphology. (C) Osteogenic differentiation of tissue pancreatic MSCs (“Materials and
methods”). Tissue pancreatic MSCs in culture without differentiation medium (left) and with differentiation medium (middle and right). After differentiation, cells stained positive
for alizarin red (right). (D) Surface expression of CCR1, CCR7, CXCR4, CXCR6, and CX3CR1 on tissue pancreatic MSCs detected by flow cytometry. (E) The percentage of
positive cells for the chemokine receptors is reported (mean SD; n 	 2) and compared with the values obtained for BM-MSCs.
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unique cell-bound CXC chemokine displaying some features of CC
chemokines and a structure resembling that of CX3CL1. The
unusual structural characters and cellular distribution of CXCR6
and its ligand, together with the fact that CXCR6-bearing T cells
are enriched in inflamed tissues, such as rheumatoid arthritis joint
lesions, atherosclerotic plaques, and chronic hepatitis C–diseased
liver, suggest that also CXCR6 could play a role in facilitating
MSC localization in inflamed tissue. A small percentage of the
MSCs analyzed expressed CCR1 or CCR7. Despite receptor
expression on a small minority of cells, the corresponding chemo-
kines CCL3, CCL19, and CCL21 were able to induce migration of
a small number of BM-MSCs. Wynn et al45 also recently reported
that cell surface levels of a chemokine receptor (CXCR4) on MSCs
can be low, with large amounts found intracellularly. It is not clear
whether the expression of chemokine receptors on a subgroup of
MSCs identifies heterogeneous MSC populations or if this is an
artifact of culture conditions.
Finally, the ability of pancreatic islets to attract BM-MSCs in
vitro and in vivo speculates a potential role of these cells in  cell
replacement. We provide evidence that BM-MSCs are attracted by
pancreatic islets in vitro and in vivo, that tissue MSCs are present in
the pancreas, and that CXCL12 and CX3CL1 play a relevant role in
migration. Several in vivo studies35-37 suggest that BM cells
contribute to pancreatic  cell regeneration,36 and it was proposed
that the cell types in the BM responsible for pancreatic endocrine
differentiation are MSCs.38,39 The role of BM-derived cells in  cell
replacement is controversial. Some evidence suggests the possibil-
ity that BM cells (including MSCs) differentiate into islet 
cells,36,38,39,54 and recently it has been suggested that human
BM-derived stem cells can be induced to transdifferentiate into
secretion competent insulin producing–cells and may serve as a
potential autologous source for cell therapy (Lijun Yang, Univer-
sity of Florida, written personal communication, August 2004).
Other reports have contradicted these findings,55,56 suggesting, in
some cases, that BM cells could be “feeder” cells for islet
differentiation, proliferation, and vascularization57 but do not
differentiate into  cells.37 Our findings do not address this issue.
In conclusion, we report that BM-MSCs migrate to a restricted
set of chemokines in vitro. To our knowledge, this is the first
comprehensive report of chemokine receptor expression on MSCs.
Harnessing the migratory potential of MSCs by modulating their
chemokine-chemokine receptor interaction may be a powerful way
to enhance hematopoietic stem cell engraftment after transplanta-
tion, increase their ability to correct inherited disorders of bone or
cartilage, or facilitate tissue repair in vivo.
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